Reimb for Cold Agglutinin Disease drug Enjaymo starts in KOR
By Eo, Yun-Ho | translator Kim, Jung-Ju
23.12.14 15:48:18
가나다라
0
Reimb listing process in progress after being approved in July in Korea
Expected to improve the treatment environment as a first-in-class treatment option
According to industry sources, Sanofi Korea has filed a reimbursement application for its Enjaymo (sutimlimab) as a treatment for hemolysis in adult patients with Cold Agglutinin Disease (CAD)
Enjaymo’ is a first-in-class humanized monoclonal antibody that is designed to selectively target and inhibit the classical complement pathway-specific serine protease, C1s. The drug was found to increase the CAD patients’ hemoglobin level and reduce profound fatigue.
CAD is a very rare type of autoimmune blood disorder where part of the body’s immune system mistakenly continues to attack
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)